Ureshino Hiroshi

ウレシノヒロシ | Ureshino Hiroshi

Affiliation and department：

Research field (3)： Cell biology , Laboratory animal science , Hematology and oncology

Research keywords (5)： CML, treatment-free remission , 多発性骨髄腫 SLAMF7 , CML stem cells , NK cell immunity, KIR and HLA , MDS, new drug

Research theme for competitive and other funds (2)：

2021 - 2025 Treatment strategy for elimination of CML stem cell using novel DNMT inhibitor
2019 - 2021 Can allelic polymorphisms of KIRs predict TFR in CML?

Papers (110)：

Taro Edahiro, Hiroshi Ureshino, Masahiro Nakamori, Takero Shindo, Tatsuo Ichinohe. Acalabrutinib and Obinutuzumab for Chronic Lymphocytic Leukemia Complicated With Peripheral Neuropathy. Cureus. 2024
Hiroshi Ureshino, Kazuharu Kamachi, Keisuke Kidoguchi, Shinya Kimura. IFN-α treatment may enable discontinuation of TKIs in NK cell-licensed patients with CML-CP. eJHaem. 2024
Hiroshi Ureshino, Shinya Kimura. Efficacy and Safety of the First-in-Class STAMP-Inhibitor Asciminib in Patients With Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia. 2024
Hiroshi Ureshino, Naoto Takahashi, Takayuki Ikezoe, Yoshihiro Kameoka, Satoshi Kimura, Noriyasu Fukushima, Tatsuo Ichinohe, Ayako Takamori, Atsushi Kawaguchi, Masatomo Miura, et al. A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial). International journal of hematology. 2024
Naho Kurisu, Tomona Hiyama, Yosuke Harada, Noriyasu Fukushima, Narutaka Katsuya, Hiroshi Ureshino, Tatsuo Ichinohe, Yoshiaki Kiuchi. Vitreoretinal Lymphoma in a Patient with Rheumatoid Arthritis with a History of Methotrexate-associated Lymphoproliferative Disorders. Ocular Immunology and Inflammation. 2024

ｍore...

MISC (140)：

枝廣太郎, 美濃達治, 樗木錬, 吉田徹巳, 杉原清香, 嬉野博志, 進藤岳郎, 一戸辰夫. 急速な胸水貯留により病勢増悪を認めた多発性骨髄腫の1例. 臨床血液. 2024. 65. 5. 468-469
嬉野博志. 【血液症候群(第3版)-その他の血液疾患を含めて-】血漿タンパクの異常クリオグロブリン血症. 日本臨床. 2024. 別冊. 血液症候群V. 204-207
嬉野博志. 慢性骨髄性白血病(CML)の無治療寛解維持達成のためのCML幹細胞制御免疫機構の解明:HLA拘束性T細胞が規定するCML関連エピトープの同定及び細胞障害性T細胞の果たす役割の解明. がん治療のあゆみ(Web). 2024. 43
嬉野博志. Acute myeloid leukemia with minimal differentiation. 日本臨床. 2024. 別冊. 血液症候群IV. 151-155
吉田徹巳, 吉田奈央, 樗木錬, 美濃達治, 枝廣太郎, 杉原清香, 嬉野博志, 一戸辰夫. 単施設におけるカプラシズマブ使用例を含む後天性血小板減少性紫斑病症例の後方視的解析. 日本血液学会学術集会. 2023. 85回. 61-61

ｍore...

Patents (4)：

Lectures and oral presentations (11)：

免疫学から見たモガムリズマブの薬理作用
(2019)
Clinical features and outcome of very elderly patient with diffuse large B-cell lymphoma
(2019)
Eficacy of DNA demethylating agents and related molecular targets in adult-T cell leukemia-lymphoma
(2019)
Efficacy of OR-21, a new oral DNA methyltransferase inhibitor in chronic myeloid leukemia
(2019)
新規デシタビンプロドラッグOR21は分化及びがん抑制遺伝子の発現を誘導する
(2019)

ｍore...

Professional career (1)：

Work history (9)：

2024/08 - Saga University
2023/08 - 2024/07 Hiroshima University Hematology and Oncology Associate Professor
2022/04 - 2023/07 Hiroshima University
2020/01 - 2022/03 佐賀大学医学部血液腫瘍内科講師
2017/04 - 2019/12 佐賀大学医学部創薬科学講座助教

Show all

Committee career (5)：

Awards (13)：

Show all

Association Membership(s) (7)：

日本造血・免疫細胞療法学会 , 日本癌学会 , 日本がん分子標的治療学会 , 日本血液学会 , 日本臨床腫瘍学会 , 日本消化器内視鏡学会 , 日本内科学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page